HIV PREVENTION PIPELINE: PRODUCTS TO WATCH

PRECLINICAL	PHASE I	PHASE II	PHASE III	IMPLEMENTATION
Hundreds of				
ARV- Based	3-Monthly DPV	Event-Driven FTC/TAF	Monthly MK-8527	Daily TDF/FTC
MPTs	On-Demand TAF + EVG	On-Demand TFV		Daily FTC/TAF
Vaccine candidates	Vaccine candidates	3-Monthly DPV + LNG		2-Monthly CAB
bNAbs candidates	Combo bNAb candidates	Combo bNAb candidates		6-Monthly LEN
The US Govt's shut down of USAID ended six critical HIV research projects. With MATRIX, the field lost an important effort to develop diverse, on-demand, and multi-purpose products, especially for young women. The ADVANCE and BRILLIANT projects were researching a range of vaccine candidates while also building African-led research agendas.		BIO-EQUIVALENCE		Monthly
		4-Monthly CAB	12-Monthly LEN	БР
acting purpose mi	ginal & Vaginal Vaccines ucosal film serts	Daily		
KEY: ARV-based MI	PTs Vaccines bNAbs	I		I

bNAb: broadly-neutralizing antibodies, CAB: Cabotegravir, DPP: dual prevention pill, DPV: Dapivirine, EVG: Elvitegravir, F/TAF: emtricitabine/tenofovir alafenamide, LEN: Lenacapavir, LNG: Levonorgestrel, TAF: tenofovir alafenamide, TDF/FTC: tenofovir disoproxil fumarate-emtricitabine